SHELBY DERENE REED

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia
    Shelby D Reed
    Center for Clinical and Genetic Economics, USA
    Infect Control Hosp Epidemiol 26:175-83. 2005
  2. ncbi request reprint Statistical considerations in economic evaluations: a guide for cardiologists
    Shelby D Reed
    Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 35:1652-6. 2014
  3. ncbi request reprint A Framework to Evaluate the Cost-Effectiveness of the NADiA ProsVue Slope to Guide Adjuvant Radiotherapy among Men with High-Risk Characteristics Following Prostatectomy for Prostate Cancer
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA Electronic address
    Value Health 17:545-54. 2014
  4. ncbi request reprint Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina Department of Medicine, Duke University School of Medicine, Durham, North Carolina Electronic address
    J Card Fail 19:611-20. 2013
  5. pmc A phase III randomized three-arm trial of physical therapist delivered pain coping skills training for patients with total knee arthroplasty: the KASTPain protocol
    Daniel L Riddle
    Departments of Physical Therapy and Orthopaedic Surgery, Virginia Commonwealth University, Richmond, VA, USA
    BMC Musculoskelet Disord 13:149. 2012
  6. pmc Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Genet Med 15:203-11. 2013
  7. pmc Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    J Card Fail 18:784-91. 2012
  8. pmc In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial)
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Am J Cardiol 110:1150-5. 2012
  9. pmc Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 5:113-9. 2012
  10. pmc Parents' reported preference scores for childhood atopic dermatitis disease states
    Joelle Y Friedman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    BMC Pediatr 4:21. 2004

Detail Information

Publications56

  1. ncbi request reprint Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia
    Shelby D Reed
    Center for Clinical and Genetic Economics, USA
    Infect Control Hosp Epidemiol 26:175-83. 2005
    ..We compared costs and outcomes of methicillin resistance in patients with S. aureus bacteremia and a single chronic condition...
  2. ncbi request reprint Statistical considerations in economic evaluations: a guide for cardiologists
    Shelby D Reed
    Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 35:1652-6. 2014
    ..The paper then highlights issues that should be considered in the interpretation of findings from economic evaluations. ..
  3. ncbi request reprint A Framework to Evaluate the Cost-Effectiveness of the NADiA ProsVue Slope to Guide Adjuvant Radiotherapy among Men with High-Risk Characteristics Following Prostatectomy for Prostate Cancer
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA Electronic address
    Value Health 17:545-54. 2014
    ..We developed a decision-modeling framework to evaluate its cost-effectiveness to guide the use of adjuvant radiotherapy (ART)...
  4. ncbi request reprint Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina Department of Medicine, Duke University School of Medicine, Durham, North Carolina Electronic address
    J Card Fail 19:611-20. 2013
    ..We compared medical resource use, costs, and health utilities between the treatment groups...
  5. pmc A phase III randomized three-arm trial of physical therapist delivered pain coping skills training for patients with total knee arthroplasty: the KASTPain protocol
    Daniel L Riddle
    Departments of Physical Therapy and Orthopaedic Surgery, Virginia Commonwealth University, Richmond, VA, USA
    BMC Musculoskelet Disord 13:149. 2012
    ..We designed a three-arm trial to determine if a pain coping skills training program, delivered prior to TKA, effectively reduces function-limiting pain following the procedure in patients with high levels of pain catastrophizing...
  6. pmc Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Genet Med 15:203-11. 2013
    ..We applied this evidence in a decision-analytic model to re-evaluate the cost-effectiveness of the assay...
  7. pmc Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    J Card Fail 18:784-91. 2012
    ..Reports that patients with heart failure and anemia incur greater costs and medical resource use have relied largely on data with limited clinical detail...
  8. pmc In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial)
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Am J Cardiol 110:1150-5. 2012
    ..In conclusion, resource use and associated medical costs in the last year of life differed markedly in patients with HF who experienced SCD and patients who died of other causes...
  9. pmc Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 5:113-9. 2012
    ..Valid cost estimation is critical to conducting economic evaluations and for program budgeting and reimbursement negotiations...
  10. pmc Parents' reported preference scores for childhood atopic dermatitis disease states
    Joelle Y Friedman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    BMC Pediatr 4:21. 2004
    ....
  11. ncbi request reprint Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    Pharmacoeconomics 26:435-46. 2008
    ..For trials in which participants are followed beyond the main study period to assess long-term outcomes, economic evaluations conducted using short-term data should be systematically updated to reflect new information...
  12. doi request reprint Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
    Shelby D Reed
    Center for Clinical and Genetic Economics and Outcomes Research and Assessment Group, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    J Clin Oncol 27:2185-91. 2009
    ....
  13. pmc Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Am J Hypertens 23:142-8. 2010
    ..The combined intervention led to a significant reduction in systolic blood pressure compared with usual care alone. We examined direct and patient time costs associated with each intervention...
  14. pmc Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 3:374-81. 2010
    ..We compared medical resource use and costs incurred by these patients during follow-up...
  15. pmc Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer
    Shelby D Reed
    Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27715, USA
    J Urol 185:841-7. 2011
    ..We estimated the cost-effectiveness of prostate cancer chemoprevention across risk groups defined by family history and number of risk alleles, and the cost-effectiveness of targeting chemoprevention to higher risk groups...
  16. doi request reprint End point selection in acute decompensated heart failure clinical trials: economic end points
    Shelby D Reed
    Department of Medicine, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Heart Fail Clin 7:529-37. 2011
    ..Integrating economic end points with concrete clinical outcomes postdischarge will provide meaningful data to evaluate a treatment's incremental value in the setting of ADHF...
  17. ncbi request reprint The economic burden of allergic rhinitis: a critical evaluation of the literature
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Pharmacoeconomics 22:345-61. 2004
    ....
  18. ncbi request reprint Economic issues and antibiotic resistance in the community
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
    Ann Pharmacother 36:148-54. 2002
    ..Multiple economic factors, at the level of physicians, patients, healthcare organizations, and pharmaceutical companies, foster poor antibiotic use...
  19. ncbi request reprint Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 17715, USA
    Int J Technol Assess Health Care 19:396-406. 2003
    ..To develop and evaluate strategies for estimating hospitalization costs in multinational clinical trials...
  20. ncbi request reprint Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 101:2574-83. 2004
    ..In the current study, the authors estimated the incremental cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC) as first-line therapy for these patients...
  21. ncbi request reprint Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
    ..We conducted a prospective economic evaluation to compare within-trial resource use, costs, and quality of life in patients receiving valsartan, captopril, or both after MI...
  22. pmc Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients
    Yanhong Li
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Clin J Am Soc Nephrol 4:428-34. 2009
    ..Staphylococcus aureus is a leading cause of infection in patients with ESRD. Clinical and economic outcomes associated with S. aureus bacteremia and other S. aureus infections in patients with ESRD were examined...
  23. ncbi request reprint Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Kevin J Anstrom
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 101:2584-92. 2004
    ..The authors estimated survival among patients with chronic myeloid leukemia for a cost-effectiveness analysis of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC)...
  24. ncbi request reprint Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Durham, NC, USA
    Am Heart J 148:122-8. 2004
    ..We sought to compare resource use, costs, and health outcomes among patients taking prescribed therapy for heart failure and randomly assigned to receive valsartan or placebo...
  25. pmc Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs
    Cassandra Moran
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Pediatr Infect Dis J 28:433-5. 2009
    ..7 vs. 20.7 days; P < 0.001) and higher inpatient costs ($133,871 vs. $56,725; P < 0.001) but lower mortality (28.3% vs. 43.5%; P < 0.001)...
  26. pmc Two self-management interventions to improve hypertension control: a randomized trial
    Hayden B Bosworth
    Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, Center for Aging and Human Development, Duke Hypertension Center, and Duke Clinical Research Institute, Duke University, Durham, North Carolina 27703, USA
    Ann Intern Med 151:687-95. 2009
    ..Fewer than 40% of persons with hypertension in the United States have adequate blood pressure (BP) control...
  27. ncbi request reprint A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, USA
    Med Decis Making 23:252-64. 2003
    ..Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations...
  28. ncbi request reprint Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis
    John J Engemann
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Infect Control Hosp Epidemiol 26:534-9. 2005
    ..To examine the clinical outcomes and costs associated with Staphylococcus aureus bacteremia among hemodialysis-dependent patients...
  29. ncbi request reprint Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia
    Jula K Inrig
    Department of Medicine, Division of Nephrology, Duke University Medical Center, Durham, NC 27705, USA
    Clin J Am Soc Nephrol 1:518-24. 2006
    ..Twelve-week mortality and costs that are associated with an episode of SAB are high in hemodialysis patients, regardless of vascular access type. Efforts should focus on the prevention of SAB in this high-risk group...
  30. ncbi request reprint Variation in the type and frequency of postoperative invasive Staphylococcus aureus infections according to type of surgical procedure
    Deverick J Anderson
    Division of Infectious Disease, Duke University Medical Center, Durham, North Carolina 27710, USA
    Infect Control Hosp Epidemiol 31:701-9. 2010
    ..To determine the epidemiological characteristics of postoperative invasive Staphylococcus aureus infection following 4 types of major surgical procedures.design. Retrospective cohort study...
  31. ncbi request reprint Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes
    Vivian H Chu
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 118:1416. 2005
    ..aureus bacteremia on patients with prosthetic devices. This investigation sought to define the clinical outcome, health care resource use, and infection-associated costs of S. aureus bacteremia in patients with prostheses...
  32. ncbi request reprint Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures
    Barbara D Alexander
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 3035, Durham, NC 27710, USA
    Diagn Microbiol Infect Dis 54:277-82. 2006
    ..Incorporating the C. albicans PNA FISH test as part of the initial identification algorithm for yeasts recovered from blood can result in substantial savings for hospitals...
  33. pmc Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections
    Cassandra Moran
    Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA
    Am J Infect Control 38:78-80. 2010
    ..04) and longer hospital stays (19.7 vs 14.5 days; P = .05) compared with early evidence of C albicans. Mortality was similar between the groups...
  34. doi request reprint Clinical outcomes and costs among patients with Staphylococcus aureus bacteremia and orthopedic device infections
    Tahaniyat Lalani
    Duke Clinical Research Institute, 2400 Pratt Street, Cube 7545, Durham, NC 27710, USA
    Scand J Infect Dis 40:973-7. 2008
    ..Patients with ODI had higher relapse of S. aureus infection, compared to bacteremic patients without ODI. Costs and outcomes were similar among ODI patients undergoing device removal and those treated with debridement and retention...
  35. doi request reprint Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease
    Tomohiko Takahashi
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University, Durham, North Carolina 27715, USA
    Nephrology (Carlton) 13:419-27. 2008
    ..This study was designed to evaluate the cost-effectiveness of AST-120, an oral adsorbent that attenuates the progression of chronic kidney disease...
  36. ncbi request reprint Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Clin Oncol 28:8-16. 2005
    ..There were no significant cost differences between patients receiving zoledronic acid and those receiving pamidronate...
  37. pmc Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation
    Christopher E Cox
    Duke University, Chapel Hill, NC, USA
    Crit Care Med 36:706-14. 2008
    ..Therefore, we aimed to determine the cost-effectiveness of the most commonly used sedatives prescribed for mechanically ventilated critically ill patients...
  38. ncbi request reprint Analytic considerations in economic evaluations of multinational cardiovascular clinical trials
    Frank M Torti
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Value Health 9:281-91. 2006
    ..Although recommendations for conducting economic evaluations have been widely disseminated, relatively little guidance has been given for conducting economic evaluations alongside clinical trials, particularly multinational trials...
  39. ncbi request reprint Conducting economic evaluations alongside multinational clinical trials: toward a research consensus
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke University Medical Centre, Durham, NC, USA
    Am Heart J 149:434-43. 2005
    ..Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies...
  40. ncbi request reprint Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Pharmacoeconomics 24:479-94. 2006
    ..We sought to compare resource use, costs and clinical outcomes between treatment groups and report the results using a cost-consequences framework...
  41. pmc Outcomes of inpatients with and without sickle cell disease after high-volume surgical procedures
    Michaela A Dinan
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Am J Hematol 84:703-9. 2009
    ..Patients with SCD who underwent cholecystectomy or hip replacement required more health care resources than patients without SCD. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  42. ncbi request reprint Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death
    Mari M Kitahata
    Department of Medicine, University of Washington, Seattle, Washington 98104, USA
    Int J STD AIDS 15:803-10. 2004
    ..2). Patients who progressed to AIDS or death had significantly higher viral loads (P = 0.01) and lower CD4 cell counts (P = 0.03) than patients who experienced virologic failure, but did not progress...
  43. ncbi request reprint Resource use and costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluation
    Mark E Patterson
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    J Card Fail 15:819-27. 2009
    ..We compared within-trial medical resource use and costs between treatments...
  44. ncbi request reprint Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey
    Amy W Law
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    J Allergy Clin Immunol 111:296-300. 2003
    ..Previous estimates of the cost of allergic rhinitis predate the substantial increase in the use of second-generation antihistamines and intranasal corticosteroids...
  45. ncbi request reprint Treatment patterns and costs associated with sessile colorectal polyps
    Jane E Onken
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Gastroenterol 97:2896-901. 2002
    ....
  46. ncbi request reprint Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis
    Jane Chang
    Duke University Medical Center, Durham, NC 27715, USA
    Arthritis Rheum 52:2366-75. 2005
    ..To describe the health state preferences of patients with osteoarthritis (OA) according to the level of pain and disability and the extent of gastrointestinal side effects from nonsteroidal antiinflammatory drugs (NSAIDs)...
  47. ncbi request reprint Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 152:500-8. 2006
    ..By examining this international trial population of high-risk patients, we sought to determine geographic variations in the use of 3 key treatments for MI...
  48. pmc Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank
    Esi Morgan Dewitt
    Department of Pediatrics, Division of Rheumatology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Ther 31:1871-80; discussion 1858. 2009
    ..The aim of this study was to identify factors associated with the initiation of biologic agents for the treatment of rheumatoid arthritis (RA) in a large US observational cohort...
  49. ncbi request reprint Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation
    Jasmina I Radeva
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Clin Transplant 19:122-9. 2005
    ..We compared within-trial costs and resource use over 1 yr of follow-up in de novo heart transplant patients randomized to everolimus 1.5 mg/d (n = 209), everolimus 3.0 mg/d (n = 211), or azathioprine (n = 214)...
  50. ncbi request reprint Characteristics of nontraumatic subarachnoid hemorrhage in the United States in 2003
    Alisa M Shea
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    Neurosurgery 61:1131-7; discussion 1137-8. 2007
    ..We examined the epidemiology and in-hospital outcomes of nontraumatic SAH in the United States...
  51. pmc Economic implications of potential changes to regulatory and reimbursement policies for medical devices
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    J Gen Intern Med 23:50-6. 2008
    ..To evaluate the impact of regulatory scenarios on the financial viability of medical device companies...
  52. ncbi request reprint Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center Durham, North Carolina, USA
    J Urol 171:1537-42. 2004
    ..We estimated the cost-effectiveness of zoledronic acid vs placebo for decreasing skeletal complications in men with prostate cancer...
  53. ncbi request reprint Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Curr Med Res Opin 21:1527-33. 2005
    ..To examine associations between early hemoglobin response and alternative measures of efficacy following treatment with an erythropoietic agent for chemotherapy-related anemia...
  54. ncbi request reprint Financial implications of a model heart failure disease management program for providers, hospital, healthcare systems, and payer perspectives
    David J Whellan
    Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Am J Cardiol 99:256-60. 2007
    ....
  55. ncbi request reprint The cost of inefficiency in US hospitals, 1985-1997
    Bimal R Shah
    Stanford University Hospitals, USA
    J Health Care Finance 30:1-9. 2003
    ..Hospital overhead costs are increasing faster than would be expected if efficiency were the primary goal of hospital management...
  56. ncbi request reprint A multinational review of recent trends and reports in dementia caregiver burden
    Frank M Torti
    University of North Carolina at Chapel Hill School of Medicine, USA
    Alzheimer Dis Assoc Disord 18:99-109. 2004
    ..Future interventions to reduce caregiver burden must consider these differences, identify patients and caregivers at greatest risk, and develop targeted programs that combine aspects of a number of interventional strategies...

Research Grants2

  1. Tools for Economic Analysis of Patient Management Interventions in Heart Failure
    Shelby Reed; Fiscal Year: 2009
    ..The TEAM-HF projects will provide clinicians and researchers with user-friendly tools to facilitate the conduct of high-quality economic evaluations of patient-focused interventions. ..
  2. Tools for Economic Analysis of Patient Management Interventions in Heart Failure
    SHELBY DERENE REED; Fiscal Year: 2010
    ..The TEAM-HF projects will provide clinicians and researchers with user-friendly tools to facilitate the conduct of high-quality economic evaluations of patient-focused interventions. ..